Intimation of the additional capacity installation at the new manufacturing unit (Unit-II) of Asston Pharmaceuticals Limited.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.6 pts more than Nifty Microcap 250 and 5.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Asston Pharmaceuticals is setting up a second manufacturing unit (Unit-II) at MIDC, Additional Ambernath, Thane, for producing pharmaceuticals and nutraceuticals. The new unit will take total capacity from 5-6 crore tablets/month to 14-15 crore tablets/month, nearly 2.5-3x the current capacity which is already running at 80% utilisation. The project involves an investment of approximately ₹6 crore, to be funded through internal accruals and IPO proceeds, and is targeted for completion by Q4 FY26. The company says the expansion is needed to meet captive requirements and growing market demand.
Positive for long-term growth as the company significantly scales up production capacity to capture rising demand, though investors should watch for execution timelines and any margin pressure during the ramp-up phase.